Pneumococcal Protein Vaccine Safety and Immunogenicity Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Adverse Effects
Interventions
DRUG

Pneumococcal protein vaccine

One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM

DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Trial Locations (1)

Unknown

ICDDR,B, Dhaka

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

NCT01764126 - Pneumococcal Protein Vaccine Safety and Immunogenicity Trial | Biotech Hunter | Biotech Hunter